By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Oncology are presented in a new report. According to news reporting out of Chicago, Illinois, by NewsRx editors, research stated, "In the present study, we investigated the anticancer effects of the mitochondrial inhibitors, metaiodobenzylguanidine (MIBG), metformin and phenformin. 131I-MIBG has been used for scintigraphic detection and the targeted radiotherapy of neuroblastoma (NB), a pediatric malignancy. Non-radiolabeled MIBG has been reported to be cytotoxic to NB cells in vitro and in vivo."
Our news journalists obtained a quote from the research from the University of Illinois, "However, the mechanisms behind its growth suppressive effects have not yet been fully elucidated. Metformin and phenformin are diabetes medications that are being considered in anticancer therapeutics. We investigated the anticancer mechanisms of action of MIBG and metformin in NB. Our data revealed that both drugs suppressed NB cell growth and that the combination drug treatment was more potent. MIBG reduced MYCN and MYC expression in MYCN-amplified and non-MYCN-amplified NB cells in a dose-and time-dependent manner. Metformin was less effective than MIBG in destabilizing MYC/MYCN. The treatment of NB cells with metformin or MIBG resulted in an increased expression of genes encoding biomarkers for favorable outcome in NB [(ephrin (EFN)B2, EFNB3, EPH receptor B6 (EPHB6), neurotrophic tyrosine kinase, receptor, type 1 (NTRK1), CD44 and Myc-interacting zinc finger protein (MIZ-1)] and tumor suppressor genes [(early growth response 1 (EGR1), EPH receptor A2 (EPHA2), growth arrest and DNA-damage-inducible, beta (GADD45B), neuregulin 1 (NRG1), TP53 apoptosis effector (PERP) and sel-1 suppressor of lin-12-like (C. elegans) (SEL1L)]. Accordingly, metformin and MIBG augmented histone H3 acetylation in these cells. Phenformin also exhibited histone modification and was more effective than metformin in destabilizing MYC/MYCN in NB cells."
According to the news editors, the research concluded: "Our data suggest that the destabilization of MYC/MYCN by MIBG, metformin and phenformin and their effects on histone modification are important mechanisms underlying their anticancer effects."
For more information on this research see: Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin. International Journal of Molecular Medicine, 2014;33(1):35-42 (see also Oncology).
Our news journalists report that additional information may be obtained by contacting S.S. Wang, Dept. of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, United States. Additional authors for this research include R. Hsiao, M.M. Limpar, S. Lomahan, T.A. Tran, N.J. Maloney, N. Ikegaki and X.X Tang.
Keywords for this news article include: Antidiabetic Agents, Drugs, Chicago, Illinois, Histones, Oncology, Metformin, Treatment, Biguanides, Phenformin, Radiotherapy, United States, Nucleoproteins, Non Sulfonylureas, Hypoglycemic Agents, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC